



1FW 3739

PATENT

I certify that on 5/13/05, which is the date I am signing this certificate, this correspondence and all attachments mentioned are being deposited in the United States Postal Service as first class in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Craig A. Slavin

Applicant: Fleishman et al.

Serial No.: 08/529,354

Filing Date: September 18, 1995

Title: Systems and Methods for Electronically Altering the Energy Emitting Characteristics of an Electrode Array to Create Different Lesion Patterns in Body Tissue

Group Art Unit: 3739

Examiner: D. Shay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

REJECTION (37 CFR §1.321(b))

Sir:

I, Craig A. Slavin, represent that I am an attorney of record in the present application and that I am authorized to sign on behalf of Boston Scientific Corporation and EP Technologies, Inc., the owners of all of the interest in the above-identified application. I hereby certify that all statements made herein are made by and for Boston Scientific Corporation and EP Technologies, Inc. The assignment applicable to the above-identified application, which was recorded on December 20, 1993 on Reel 6846, Frame 0577, assigns all of the interest to EP Technologies, Inc. EP Technologies, Inc. is, in turn, a wholly owned subsidiary of Boston Scientific Corporation.

United States Patent No. 6,049,732 is assigned to EP Technologies, Inc. Scimed Life Systems, Inc., which is the assignee of United States Patent No. 6,071,281, changed its name to Boston Scientific Scimed, Inc. effective January 1, 2005. Boston Scientific Scimed, Inc. is co-owned by Boston Scientific Corporation and Boston

Scientific Whayne Corporation. Boston Scientific Whayne Corporation is, in turn, a wholly owned subsidiary of Boston Scientific Corporation.

Boston Scientific Corporation and EP Technologies, Inc. hereby disclaim the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory period of United States Patent Nos. 6,049,732 and 6,071,281, as presently shortened by any terminal disclaimer, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent Nos. 6,049,732 and 6,071,281, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns.

Boston Scientific Corporation and EP Technologies, Inc. do not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent Nos. 6,049,732 and 6,071,281, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer.


A check in the sum of \$110.00 (37 CFR §1.20(d)) is submitted herewith. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0638. Should such fees

be associated with an extension of time, applicant respectfully requests that this paper be considered a petition therefor.

5/10/05
Date

Henricks, Slavin & Holmes LLP
840 Apollo Street, Suite 200
El Segundo, CA 90245
(310) 563-1458
(310) 563-1460 (Facsimile)

Respectfully Submitted,



Craig A. Slavin
Reg. No. 35,362
Attorney for Applicant